BioMark Diagnostics Inc. (BMKDF)
BioMark Diagnostics Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Richmond, BC, CA. The stock last traded at $0.41, up 0.00% on the session, giving a market capitalisation of $42.9M. On trailing twelve-month figures it carries a trailing P/E of -40.74, a net margin of -5127.1%. Its beta of -0.31 implies it has historically moved less than the broad market.
BioMark Diagnostics Inc. is an oncology-focused firm that develops sophisticated diagnostic tools for cancer. These solutions are designed to aid in the identification of the disease, its ongoing monitoring, and the assessment of initial therapeutic interventions. The company has a research partnership with the Icahn School of Medicine, under which they conduct clinical studies concentrating on the early detection of lung cancer. Established in 2014, BioMark Diagnostics Inc. has its main office in Richmond, Canada, and functions as a subsidiary of Biomark Technologies Inc.
BioMark Diagnostics Inc. is most often compared with the following Healthcare names: